Phase I study to investigate the safety and efficacy of TUR-002 for the treatment of Posttraumatic Stress Disorder (PTSD).
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2015
At a glance
- Drugs Ketamine (Primary)
- Indications Post-traumatic stress disorders
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2015 New trial record
- 12 Nov 2015 According to the media release of Turing Pharmaceuticals, this trial is planned to initiate by first quarter of 2016.